



**CHARITY COMMISSION
FOR ENGLAND AND WALES**

Trustees' Annual Report for the period

From 01.01.2020

To

31.12.2020

Charity name: FAIR (FUNDING AUTO IMMUNE RESEARCH)

Charity registration number: 1176388

Objectives and Activities

	SORP reference	
Summary of the purposes of the charity as set out in its governing document	Para 1.17	The objects of the charity are to preserve and protect the health of sufferers of autoimmune conditions and diseases by: (i) promoting research for the public benefit into developing treatments and funding a cure for autoimmune conditions and diseases, including their prevention, and to disseminate the useful results of such research; (ii) relieving sickness amongst persons who are suffering from an autoimmune condition or disease; and (iii) advancing the education of the public in general on the subject of autoimmune conditions and diseases.
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	Fundraising: sale of Christmas Cards; hosting of a Christmas Carol Service. Application of funds raised: award of £14,300 to Drs Oni and Wright of Alder Hey Hospital towards developing the 'IgA-VAS' scoring tool and discovering urinary biomarkers in childhood immunoglobulin A vasculitis; decision to award £15,000 over a three year period to Dr Pain of Alder Hey Hospital and Dr Chieng of Royal Manchester Children's Hospital to research immunogenetic factors in juvenile onset connective tissue disease.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	Confirmed

Additional information (optional)

You may choose to include further statements where relevant about:

	SORP reference	
Policy on grant making	Para 1.38	
Policy on social investment including program related investment	Para 1.38	
Contribution made by volunteers	Para 1.38	
Other		

Achievements and Performance

	SORP reference	
Summary of the main achievements of the charity, identifying the difference the charity's work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	The charity provided £14,300 to Drs Oni and Wright of Alder Hey Hospital towards developing the 'IgA-VAS' scoring tool and discovering urinary biomarkers in childhood immunoglobulin A vasculitis. Immunoglobulin (Ig) A vasculitis (IgAV; formerly Henoch Schönlein Purpura) is the most common form of vasculitis in children. Vasculitis is where the blood vessels in the body get swollen and inflamed. In this condition it causes an obvious rash that leads to children presenting for medical attention. It also causes children to get sore joints, tummy pains and inflamed kidneys. The only long-term problem linked to this condition is due to the inflamed kidneys and in 1-2 in every 100 children it will cause devastating end stage kidney failure. There is no way of predicting who will get kidney problems and no understanding of what causes it to try to stop it before damage has happened. The aim of this study is to support a medical student to complete a project to develop a scoring tool for doctors to rank how severe the condition is and to study urine samples from children with this condition to get initial data that may help to identify clues in the urine to predict who may get kidney problems.

		The charity also agreed to provide £15,000 over a three year period to Dr Pain of Alder Hey Hospital and Dr Chieng of Royal Manchester Children's Hospital to research immunogenetic factors in juvenile onset connective tissue disease. Connective tissue diseases (CTD) are conditions that affect a person's immune system and can result in severe damage to any organ in the body, threatening a person's well-being and long-term survival. CTD include disorders such as systemic lupus erythematosus, scleroderma and dermatomyositis. Some children and young people (CYP) with CTD have features of more than one of these conditions (mixed or overlap CTD) or don't fulfil criteria for a specific disease (undifferentiated CTD). The underlying causes of CTD are incompletely understood across age groups. This results in low awareness and delayed diagnosis, with lack of effective treatments targeting the cause of the disease. CYP represent an almost ideal study population because compared to adults they have less/no other illnesses, more often have undifferentiated/overlap CTD and have more severe disease. The study proposes that changes in genes (instructions) which are important for the immune system play a central role in undifferentiated, mixed/overlap CTD and may play a larger role in CYP disease than that which starts in adulthood. This is based on findings from other CTD, together with the young age at disease onset and increased severity in children. The study will investigate causes of CTD in CYP and compare findings to those in adults. This increased understanding of what is causing and driving disease may allow earlier diagnosis and will allow doctors to target future treatment in clinical studies to the exact cause of the condition with increased effect and reduced side-effects.
--	--	---

Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectives set	Para 1.41	
Performance of fundraising activities against objectives set	Para 1.41	

Investment performance against objectives	Para 1.41	
Other		

Financial Review

Review of the charity's financial position at the end of the period	Para 1.21	The charity held cash at bank in the amount of £24,748 at the end of the period
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	The reserves are held in order to fund future research projects approved by the trustees.
Amount of reserves held	Para 1.22	£24,748
Reasons for holding zero reserves	Para 1.22	N/A
Details of fund materially in deficit	Para 1.24	N/A
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	N/A

Additional information (optional)

You may choose to include further statements where relevant about:

The charity's principal sources of funds (including any fundraising)	Para 1.47	Social events; sales of Christmas cards; donations from supporters
Investment policy and objectives including any social investment policy adopted	Para 1.46	N/A
A description of the principal risks facing the charity	Para 1.46	N/A
Other		

Structure, Governance and Management

Description of charity's trusts:		
Type of governing document (trust deed, royal charter)	Para 1.25	CIO Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	CIO
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	The board of trustees acting collectively identifies and appoints trustees

Additional information (optional)

You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction and training of trustees	Para 1.51	
The charity's organisational structure and any wider network with which the charity works	Para 1.51	
Relationship with any related parties	Para 1.51	
Other		

Reference and Administrative details

Charity name	FAIR (FUNDING AUTO IMMUNE RESEARCH)
Other name the charity uses	
Registered charity number	1176388
Charity's principal address	Pen-y-Gardden Hall, Pen-y-Gardden, Tatham Road, Ruabon, Wrexham LL14 6RE

Names of the charity trustees who manage the charity

	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
1	Mrs Grainne Dennison	Chair		Trustees collectively
2	Dr Gavin Cleary			Trustees collectively
3	Mrs Alexandra Bould			Trustees collectively
4	Mrs Alexandra Abberton			Trustees collectively
5	Mr John Melia			Trustees collectively
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				

Corporate trustees – names of the directors at the date the report was approved

Director name		

Name of trustees holding title to property belonging to the charity

Trustee name	Dates acted if not for whole year	

Funds held as custodian trustees on behalf of others

Description of the assets held in this capacity	
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity's objects	
Details of arrangements for safe custody and segregation of such assets from the charity's own assets	

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address

Name of chief executive or names of senior staff members (Optional information)

--

Exemptions from disclosure

Reason for non-disclosure of key personnel details

--


Other optional information

--

Declarations

The trustees declare that they have approved the trustees' report above.

Signed on behalf of the charity's trustees

Signature(s)		
Full name(s)	John Anthony Melia	
Position (eg Secretary, Chair, etc)	Trustee	

Date

23.10.2021



CHARITY COMMISSION
FOR ENGLAND AND WALES

FAIR (FUNDING AUTO IMMUNE RESEARCH)

No (if any)
1176388

Receipts and payments accounts

CC16a

For the period
from

Period start date
01/01/2020

To

Period end date
31/12/2020

Section A Receipts and payments

	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
A1 Receipts					
	6,693	-	-	6,693	16,445
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total (Gross income for AR)	6,693	-	-	6,693	16,445
A2 Asset and investment sales, (see table).					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total receipts	6,693	-	-	6,693	16,445
A3 Payments					
	15,609	-	-	15,609	2,743
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
Sub total	15,609	-	-	15,609	2,743
A4 Asset and investment purchases, (see table)					
	-	-	-	-	-
	-	-	-	-	-
Sub total	-	-	-	-	-
Total payments	15,609	-	-	15,609	2,743
Net of receipts/(payments)	- 8,916	-	-	- 8,916	13,702
A5 Transfers between funds	-	-	-	-	-
A6 Cash funds last year end	33,664	-	-	33,664	-
Cash funds this year end	24,748	-	-	24,748	13,702

Section B Statement of assets and liabilities at the end of the period

Categories	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B1 Cash funds	Cash at Bank	24,748	-	-
		-	-	-
		-	-	-
	Total cash funds	24,748	-	-
	(agree balances with receipts and payments account(s))	OK	OK	OK
		Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
B2 Other monetary assets		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
B3 Investment assets		Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
B4 Assets retained for the charity's own use		Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
B5 Liabilities		Fund to which liability relates	Amount due (optional)	When due (optional)
			-	
			-	
			-	
			-	
			-	

Signed by one or two trustees on behalf of all the trustees	Signature	Print Name	Date of approval
		JOHN MELIA	23.10.2021